Researchers have used TissueGnostics' advanced imaging and analysis tools to detect and quantify two cell types: the PD-1+ regulatory T cells (Treg)/PD-1+CD8+ cytotoxic T cells (CTL) ratio and ...

Efficacy and safety of serplulimab-based therapy in HER2-negative advanced gastric cancer: A real-world study. The combination of PD-1 inhibitor with chemotherapy ± salvage chemoradiotherapy for local ...

Camrelizumab combined with paclitaxel and nedaplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESPRIT): A phase II, single-arm, exploratory research. This is an ...

First overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study will be presented on October 18 at the European Society for Medical Oncology (ESMO) 2025 Congress These data support ...

The MATTERHORN trial showed improved EFS and OS with durvalumab plus chemotherapy in gastric/GEJ cancer patients compared to chemotherapy alone. Durvalumab treatment resulted in a higher pCR rate and ...